CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Net Cash Inflow / Outflow History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Net Cash Inflow / Outflow | ₹-1.39 Cr | ₹0.06 Cr | ₹-11 Cr | ₹7.71 Cr |
What is the latest Net Cash Inflow / Outflow ratio of CORONA REMEDIES ?
| Year | Net Cash Inflow / Outflow |
|---|---|
| Mar2026 | ₹-1.39 Cr |
| Mar2025 | ₹0.06 Cr |
| Mar2024 | ₹-11 Cr |
| Mar2023 | ₹7.71 Cr |
How is Net Cash Inflow / Outflow of CORONA REMEDIES Trending?
| Years | Net Cash Inflow / Outflow | % Change | |
|---|---|---|---|
| Mar2026 | ₹-1.39 Cr | Negative | |
| Mar2025 | ₹0.06 Cr | Positive | |
| Mar2024 | ₹-11 Cr | Negative | |
| Mar2023 | ₹7.71 Cr | - | |
Compare Net Cash Inflow / Outflow of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹13,245.8 Cr | 0% | 0.9% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹447,476.0 Cr | -0.1% | -2.4% | 13.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹254,764.0 Cr | 2.7% | 12.9% | 54.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,423.0 Cr | 1.8% | 2.5% | 40.9% | Stock Analytics | |
| CIPLA | ₹111,484.0 Cr | 0.6% | -3.8% | -11.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,005.0 Cr | 3.3% | 1.3% | -7.6% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 0% |
0.9% |
|
| SENSEX | 0.7% |
-3.5% |
-9.2% |
You may also like the below Video Courses